Moderna Inc MRNA shares are trading higher by 7.2% at $163.54 Wednesday afternoon after Deutsche Bank upgraded the stock from Sell to Hold and announced a $175 price target.
Shares of vaccine companies were otherwise trading lower during Tuesday's session. Over the past 4 trading sessions, Moderna's stock has fallen approximately 12.6% from the $175 level to the $152 level.
See Also: Why DraftKings Shares Are Ripping Higher Today
Moderna is a commercial-stage biotech that was founded in 2010. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
Moderna has a 52-week high of $497.49 and a 52-week low of $117.34.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
